Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01625234
Title Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Xcovery Holding Company, LLC
Indications

Advanced Solid Tumor

Therapies

Ensartinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST